3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
299
Neoplasms
181
Breast Neoplasms
168
Neoplasm Metastasis
104
Colorectal Neoplasms
104
Melanoma
101
Multiple Myeloma
94
Prostatic Neoplasms
89
Ovarian Neoplasms
80
Recurrence
79
Carcinoma, Renal Cell
74
Lung Neoplasms
70
Squamous Cell Carcinoma of Head and Neck
66
Stomach Neoplasms
65
Lymphoma, Non-Hodgkin
61
Leukemia, Lymphocytic, Chronic, B-Cell
57
Pancreatic Neoplasms
55
Leukemia, Myeloid, Acute
54
Carcinoma, Hepatocellular
48
Urinary Bladder Neoplasms
45
Triple Negative Breast Neoplasms
45
Small Cell Lung Carcinoma
44
Lymphoma, Large B-Cell, Diffuse
44
Lymphoma, Follicular
40
Head and Neck Neoplasms
40
Lymphoma
38
Parkinson Disease 4, Autosomal Dominant Lewy Body
37
Glioblastoma
36
Endometrial Neoplasms
36
Uterine Cervical Neoplasms
34
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
INDUSTRY
×
Biochemically Recurrent Prostate Cancer
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled